Headlines about AveXis (NASDAQ:AVXS) have trended somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AveXis earned a news impact score of 0.19 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.485469092275 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Accern’s analysis:
- MARKET SNAPSHOT: S&P 500 Set For Another Historic Run, With U.S. Jobs Data On Deck (foxbusiness.com)
- BRIEF-Avexis Inc Plans To Request A Pre-BLA Meeting For AVXS-101 In Q2 (reuters.com)
- AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1 (finance.yahoo.com)
- AveXis shares down more than 7% after FDA news (finance.yahoo.com)
- AveXis (AVXS) Rating Reiterated by Chardan Capital (americanbankingnews.com)
Shares of AveXis (AVXS) opened at $102.08 on Friday. AveXis has a 12 month low of $50.56 and a 12 month high of $116.15. The firm has a market capitalization of $3,260.00 and a P/E ratio of -18.29.
AveXis (NASDAQ:AVXS) last issued its earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same period in the prior year, the business posted ($0.87) earnings per share. research analysts forecast that AveXis will post -6.23 earnings per share for the current year.
AVXS has been the topic of several analyst reports. Royal Bank of Canada initiated coverage on AveXis in a report on Thursday, September 14th. They set a “sector perform” rating and a $92.00 target price on the stock. Wells Fargo & Co restated an “outperform” rating on shares of AveXis in a research note on Friday, September 29th. BMO Capital Markets restated an “outperform” rating and set a $123.00 price objective on shares of AveXis in a research note on Saturday, September 30th. Citigroup raised their price objective on AveXis from $100.00 to $116.00 and gave the company a “buy” rating in a research note on Monday, October 2nd. Finally, UBS Group restated a “buy” rating and set a $122.00 price objective (up previously from $95.00) on shares of AveXis in a research note on Tuesday, October 3rd. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $111.94.
In other news, VP Andrew F. Knudten sold 2,000 shares of AveXis stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $94.48, for a total value of $188,960.00. Following the completion of the transaction, the vice president now owns 7,000 shares in the company, valued at approximately $661,360. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $101.46, for a total value of $1,521,900.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 67,340 shares of company stock valued at $6,840,745. Insiders own 18.60% of the company’s stock.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.